R&D Decentralised trials: beyond the pandemic The adoption of decentralised activities was a major factor in allowing clinical trials to continue during the early stages of the pandemic.
News EC clears first treatment for high-risk smouldering multiple... Johnson & Johnson’s Janssen-Cilag has secured European Commission approval for a new indication of its subcutaneous formulation of DARZALEX
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
